Fused imidazolium derivatives
OwnerAkira Matsuhisa, Isao Kinoyama +4inventors
InventorsAkira Matsuhisa, Isao Kinoyama, Akira Toyoshima, Takahito Nakahara, Masahiro Takeuchi, Minoru Okada
Life of this patent
Estimating the term…
Abstract
This invention relates to medicaments, particularly novel fused imidazolium derivatives useful for the treatment of cancers and novel synthetic intermediate compounds thereof. The novel imidazolium derivatives fused with an aryl or heteroaryl ring, characterized in that the 1- and/or 3-position is substituted by an alkyl group etc. having a substituent selected from the group consisting of —ORa, —SRa and the like, have excellent anti-tumor activity and low toxicity and are useful as anticancer agents having wide margins of safety. 1
Claims12
A fused imidazolium derivative represented by the following general formula (I)
- 115
- (wherein symbols in the formula have the following meanings;
- R1 and R2:
- the same or different from each other and each represents -(lower alkyl having one or more substituents selected from group B), -(lower alkenyl having one or more substituents selected from group B), -(lower alkynyl having one or more substituents selected from group B), -RinD, -lower alkyl, -lower alkenyl or -lower alkynyl, with the proviso that at least one of R1 and R2 is -(lower alkyl having one or more substituents selected from group B), -(lower alkenyl having one or more substituents selected from group B), -(lower alkynyl having one or more substituents selected from group B), -(cycloalkyl having one or more substituents) or -(five- to seven-membered saturated heterocyclic ring which may have one or more substituents),
- group B:
- —ORa, —SRa, -prodrug-formed OH, —O-lower alkylene-ORa, —O-lower alkylene-O-lower alkylene-ORa, —O-lower alkylene-NRaRb, —O-lower alkylene-O-lower alkylene-NRaRb, —O-lower alkylene-NRc-lower alkylene-NRaRb, —OCO—NRaRb, —SORa, —SO2Ra, —SO2NRaRb, NRaSO2Rb, —CO2H, —NRaRb, —NRc-lower alkylene-NRaRb, —N(-lower alkylene-NRaRb)2, -RinD, —NO2, —CN, -halogen, —CO2Ra, —COO−, —CONRaRb, —CONRa—O—Rb, —NRa—CORb, —NRa—CO—NRbRc, —OCORa and —CO—Ra,
- Ra, Rb and Rc:
- the same or different from one another and each represents —H, -lower alkyl, -lower alkylene-RinD or -RinD,
- RinD:
- -(five- to seven-membered saturated heterocyclic ring which may have one or more substituents), -(cycloalkyl which may have one or more substituents), -(cycloalkenyl which may have one or more substituents), -(aryl which may have one or more substituents) or -(heteroaryl which may have one or more substituents),
- R3:
- —H or -(lower alkyl which may have one or more substituents), or R2 and R3 may together form a lower alkylene having from 2 to 5 carbon atoms which may be interrupted with O, S or NR4 (R4:
- —H or -lower alkyl),
- ring A:
- aryl ring which may have one or more substituents or heteroaryl ring which may have one or more substituents, and
- X−:
- counter anion, with the proviso that X− does not exist when the substituent —COO− of the group B forms intramolecular salt with imidazolium cation,
- with the proviso that compounds having the following combinations of R1 and R2 are excluded:
- (1) one is -lower alkylene-(aryl which may have one or more substituents) and the other is —CH3, —(CH2)3CH3 or -phenyl,
- (2) one is -lower alkylene-CO-(aryl which may have one or more substituents) and the other is —(CH2)2CH(CH3)2 or —(CH2)3CH3, or
- (3) R1 and R2 are both -benzyl, —(CH2)2OC2H5 or —(CH2)2O—COCH3.)
A 2-acylamino-3-amino-1,4-quinone derivative represented by the following general formula (II) or a salt thereof
- 116
- (wherein symbols in the formula have the following meanings;
- R1 and R2:
- the same or different from each other and each represents -(lower alkyl having one or more substituents selected from group B), -(lower alkenyl having one or more substituents selected from group B), -(lower alkynyl having one or more substituents selected from group B), -RinD, -lower alkyl, -lower alkenyl or -lower alkynyl, with the proviso that at least one of R1 and R2 is -(lower alkyl having one or more substituents selected from group B), -(lower alkenyl having one or more substituents selected from group B), -(lower alkynyl having one or more substituents selected from group B), -(cycloalkyl having one or more substituents) or -(five- to seven-membered saturated heterocyclic ring which may have one or more substituents),
- group B:
- —ORa, —SRa, -prodrug-formed OH, —O-lower alkylene-ORa, —O-lower alkylene-O-lower alkylene-ORa, —O-lower alkylene-NRaRb, —O-lower alkylene-O-lower alkylene-NRaRb, —O-lower alkylene-NRc-lower alkylene-NRaRb, —OCO—NRaRb, —SORa, —SO2Ra, —SO2NRaRb, —NRa—SO2Rb, —CO2H, —NRaRb, —NRc-lower alkylene-NRaRb, —N(-lower alkylene-NRaRb)2, -RinD, —NO2, —CN, -halogen, —CO2Ra, CO—NRaRb, —CONRa—O—Rb, —NRa—CORb, —NRa—CO—NRbRc, —OCORa and —CO—Ra,
- Ra, Rb and Rc:
- the same or different from one another and each represents —H, -lower alkyl, -lower alkylene-RinD or -RinD,
- RinD:
- -(five- to seven-membered saturated heterocyclic ring which may have one or more substituents), -(cycloalkyl which may have one or more substituents), -(cycloalkenyl which may have one or more substituents), -(aryl which may have one or more substituents) or -(heteroaryl which may have one or more substituents),
- R3:
- —H or -(lower alkyl which may have one or more substituents), or R2 and R3 may together form a lower alkylene having from 2 to 5 carbon atoms which may be interrupted with O, S or NR4 (R4:
- —H or -lower alkyl), and
- ring A:
- aryl ring which may have one or more substituents or heteroaryl ring which may have one or more substituents,
- with the proviso that compounds of the following table are excluded;
- 27 TABLE 1 (II-E) 117 Comp X R —R1 —R2 —R3 E-1 CH H —Me —CH2-(3,4-Cl—Ph) —Me E-2 CH H —CH(Me)2 —CH2-(3,4-Cl—Ph) —Me E-3 CH H —CH2—Ph -(4-MeO—Ph) —Me E-4 CH H —CH2—Ph -(3-Br—Ph) —Me E-5 CH H —CH2—Ph —CH2(4-F—Ph) —Me E-6 CH H —(CH2)2—Ph —CH2(4-F—Ph) —Me E-7 CH H —(CH2)2—OH —Me —Me E-8 CH H —(CH2)2—OH —CH2—Ph —Me E-9 CH H —(CH2)2—OH -(4-MeO—Ph) —Me E-10 CH H —(CH2)2—OH -(4-MeCO—Ph) —Me E-11 CH H —(CH2)2—OH -(3-Br—Ph) —Me E-12 CH H —(CH2)2—Cl —CH2CO2Et —Me E-13 CH H —CH(Me)—CO2H —Me —Me E-14 CH H —CH(Me)—CONHMe —Me —Me E-15 CH H —CH(Me)—CONHMe —CH(Me)2 —Me E-16 CH H —CH(Me)—CONHMe 118 —Me E-17 CH H —CH(Me)—CONHMe —Me —(CH2)2Me E-18 CH H —CH(Me)—CONHMe —Me —CH(Me)2 E-19 CH H —CH(Me)—CONHOMe —Me —Me E-20 N H —CH(Me)—CONHMe —Me —Me E-21 N Me —CH(Me)—CONHMe —Me —Me E-22 CH H 119 —Me —Me
- (in this table, Comp means compound number, Me means methyl group, Et means ethyl group and Ph means phenyl group, and in the case of a substituted phenyl group, the substituent is shown before Ph together with the substituting position, e.g., 3,4-Cl—Ph represents 3,4-dichlorophenyl).
A fused imidazole derivative represented by the following general formula (III) or a salt thereof
- 120
- (wherein symbols in the formula have the following meanings;
- R1:
- -(lower alkyl having one or more substituents selected from group B), -(lower alkenyl having one or more substituents selected from group B), -(lower alkynyl having one or more substituents selected from group B) or -(cycloalkyl having one or more substituents), with the proviso that a lower alkyl group having one or more substituents selected from the group consisting of —NH2, —NMe2, —NEt2, —OH, -halogen and -(phenyl which may be substituted by —Cl, —F, —Me or —OMe) is excluded,
- group B:
- ORa, —SRa, -prodrug-formed OH, —O-lower alkylene-ORa, —O-lower alkylene-O-lower alkylene-ORa, —O-lower alkylene-NRaRb, —O-lower alkylene-O-lower alkylene-NRaRb, —O-lower alkylene-NRc-lower alkylene-NRaRb, —OCO—NRaRb, —SORa, —SO2Ra, —SO2NRaRb, —NRa—SO2Rb, —CO2H, —NRaRb, —NRc-lower alkylene-NRaRb, —N(-lower alkylene-NRaRb)2, -RinD, —NO2, —CN, -halogen, —CO2Ra, —CONRaRb, —CONRa—O—Rb, —NRa—CORb, —NRa—CO—NRbRc, —OCORa and —CO—Ra,
- Ra, Rb and Rc:
- the same or different from one another and each represents —H, -lower alkyl, -lower alkylene-RinD or -RinD,
- RinD:
- -(five- to seven-membered saturated heterocyclic ring which may have one or more substituents), -(cycloalkyl which may have one or more substituents), -(cycloalkenyl which may have one or more substituents), -(aryl which may have one or more substituents) or -(heteroaryl which may have one or more substituents),
- R3:
- —H or -(lower alkyl which may have one or more substituents), and
- ring A:
- aryl ring which may have one or more substituents or heteroaryl ring which may have one or more substituents).
Dependencies are inferred from the claim text.